Loading
LB2102 is an experimental CAR-T cell therapy for small cell lung cancer, made from a patient's own immune cells and aimed at the protein DLL3. Legend Biotech licensed it to Novartis in November 2023.
LB2102 is Legend Biotech's autologous CAR-T cell therapy directed at DLL3. On 13 November 2023 Legend announced an exclusive global licence giving Novartis worldwide rights to develop, manufacture and sell its DLL3 CAR-T therapies, including LB2102, with USD 100 million upfront; Novartis may make them on its T-Charge manufacturing platform, and Legend was to run the US phase 1 trial. The FDA cleared the investigational new drug application in 2022 and granted orphan drug designation in 2023. The phase 1 trial (NCT05680922), sponsored by Legend Biotech USA, started in July 2023 in extensive-stage small cell lung cancer and large cell neuroendocrine carcinoma of the lung, and the registry now lists it as active but no longer recruiting. No results are recorded here.
A patient's own T cells are collected and engineered with a chimeric antigen receptor that recognises DLL3, a protein on small cell lung cancer cells, then infused back to attack the cancer. Connects to DLL3.
1.LB2102 slips into a pocket on DLL3.
| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2023-11-13 | Legend Biotech to Novartis LB2102, DLL3-directed CAR-T for small cell lung cancer, and other DLL3 CAR-T candidates | Licence | $100m | up to $1.01bn | source |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"LB2102" OR ABSTRACT:"LB2102") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LB2102, not a curated reading list.
Shares DLL3, Small-cell lung cancer and the tags pipeline, deal-asset.
Shares DLL3, Small-cell lung cancer and the tags pipeline, deal-asset.
Shares Novartis and the tags pipeline, deal-asset.
Shares the tags pipeline, deal-asset.
Shares the tags pipeline, deal-asset.
Shares the tags pipeline, deal-asset.
Shares the tags pipeline, deal-asset.
Shares the tags pipeline, deal-asset.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/